Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10191468,half life,The half life of Atosiban was 18 min and the total body clearance was 3301 ml/min.,"Atosiban, an oxytocin receptor blocking agent: pharmacokinetics and inhibition of milk ejection in dairy cows. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10191468/),min,18,9213,DB00107,Oxytocin
,10191468,total body clearance,The half life of Atosiban was 18 min and the total body clearance was 3301 ml/min.,"Atosiban, an oxytocin receptor blocking agent: pharmacokinetics and inhibition of milk ejection in dairy cows. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10191468/),[ml] / [min],3301,9214,DB00107,Oxytocin
,30472591,m/z,The analytes were monitored using selected reaction monitoring (SRM) mode with transitions at m/z 420.1→248.1 for cligosiban and m/z 304.1→161.1 for IS.,"Pharmacokinetics, bioavailability and metabolism of cligosiban, an antagonist of oxytocin receptor, in rat by liquid chromatography hyphenated with electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472591/),,420.1,12305,DB00107,Oxytocin
,30472591,m/z,The analytes were monitored using selected reaction monitoring (SRM) mode with transitions at m/z 420.1→248.1 for cligosiban and m/z 304.1→161.1 for IS.,"Pharmacokinetics, bioavailability and metabolism of cligosiban, an antagonist of oxytocin receptor, in rat by liquid chromatography hyphenated with electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472591/),,248.1,12306,DB00107,Oxytocin
,30472591,m/z,The analytes were monitored using selected reaction monitoring (SRM) mode with transitions at m/z 420.1→248.1 for cligosiban and m/z 304.1→161.1 for IS.,"Pharmacokinetics, bioavailability and metabolism of cligosiban, an antagonist of oxytocin receptor, in rat by liquid chromatography hyphenated with electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472591/),,304.1,12307,DB00107,Oxytocin
,30472591,m/z,The analytes were monitored using selected reaction monitoring (SRM) mode with transitions at m/z 420.1→248.1 for cligosiban and m/z 304.1→161.1 for IS.,"Pharmacokinetics, bioavailability and metabolism of cligosiban, an antagonist of oxytocin receptor, in rat by liquid chromatography hyphenated with electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472591/),,161.1,12308,DB00107,Oxytocin
,30472591,oral bioavailability,"According to the current results, the oral bioavailability of cligosiban was 63.82%.","Pharmacokinetics, bioavailability and metabolism of cligosiban, an antagonist of oxytocin receptor, in rat by liquid chromatography hyphenated with electrospray ionization tandem mass spectrometry. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472591/),%,63.82,12309,DB00107,Oxytocin
,20027670,pK(i),"This led to the 2', 4'-difluorophenyl dimethylamide 40, a highly potent (pK(i) =9.2) and selective OT antagonist (>1,000-fold selectivity vs. the human vasopressin receptors V1a, V2, and V1b) with good oral bioavailability (>50%) in the rat and dog.","The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),,9.2,12685,DB00107,Oxytocin
>,20027670,oral bioavailability,"This led to the 2', 4'-difluorophenyl dimethylamide 40, a highly potent (pK(i) =9.2) and selective OT antagonist (>1,000-fold selectivity vs. the human vasopressin receptors V1a, V2, and V1b) with good oral bioavailability (>50%) in the rat and dog.","The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),%,50,12686,DB00107,Oxytocin
,20027670,K(i),Retosiban has sub-nanomolar affinity (K(i) =0.65 nM) for the oxytocin receptor with >1400-fold selectivity over the closely related vasopressin receptors.,"The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),nM,0.65,12687,DB00107,Oxytocin
>,20027670,IC(50),"It has good solubility, low protein binding and has a good Cyp450 profile with no significant inhibition IC(50) >100 µM.","The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),μM,100,12688,DB00107,Oxytocin
,16620295,Ki,2. RWJ-351647 displaced (3)H-AVP binding from cloned human V(2) and V(1A) receptors with Ki values of 1 nmol/L and 24 nmol/L.,"Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),[nM] / [l],1,16997,DB00107,Oxytocin
,16620295,Ki,2. RWJ-351647 displaced (3)H-AVP binding from cloned human V(2) and V(1A) receptors with Ki values of 1 nmol/L and 24 nmol/L.,"Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),[nM] / [l],24,16998,DB00107,Oxytocin
,16620295,Ki,"In assays using transfected HEK293 cells expressing either human or rat V(2) receptors, RWJ-351647 inhibited AVP-induced cAMP accumulation with Ki values of 3 nmol/L and 6 nmol/L, respectively.","Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),[nM] / [l],3,16999,DB00107,Oxytocin
,16620295,Ki,"In assays using transfected HEK293 cells expressing either human or rat V(2) receptors, RWJ-351647 inhibited AVP-induced cAMP accumulation with Ki values of 3 nmol/L and 6 nmol/L, respectively.","Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),[nM] / [l],6,17000,DB00107,Oxytocin
,16620295,bioavailable,4. Pharmacokinetic studies in rats showed RWJ-351647 to be 41.9% bioavailable after a single oral administration.,"Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),%,41.9,17001,DB00107,Oxytocin
,16620295,oral bioavailability,"After repeated daily dosing over 5 days, the oral bioavailability remained at 43.9% with no change in the compound peak plasma levels or clearance rate.","Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),%,43.9,17002,DB00107,Oxytocin
,9552454,elimination half-life (t1/2),"For comparative purposes, the mean values determined for the elimination half-life (t1/2), volume of distribution (Vd), and the total body clearance (CL) following intravenous injection of OT were 2.9 +/- 0.2 min, 85.3 +/- 6.7 ml, and 20.4 +/- 2.03 ml/min, respectively.",Transmucosal delivery of oxytocin to rabbits using a mucoadhesive buccal patch. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552454/),min,2.9,31737,DB00107,Oxytocin
,9552454,volume of distribution (Vd),"For comparative purposes, the mean values determined for the elimination half-life (t1/2), volume of distribution (Vd), and the total body clearance (CL) following intravenous injection of OT were 2.9 +/- 0.2 min, 85.3 +/- 6.7 ml, and 20.4 +/- 2.03 ml/min, respectively.",Transmucosal delivery of oxytocin to rabbits using a mucoadhesive buccal patch. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552454/),ml,85.3,31738,DB00107,Oxytocin
,9552454,total body clearance (CL),"For comparative purposes, the mean values determined for the elimination half-life (t1/2), volume of distribution (Vd), and the total body clearance (CL) following intravenous injection of OT were 2.9 +/- 0.2 min, 85.3 +/- 6.7 ml, and 20.4 +/- 2.03 ml/min, respectively.",Transmucosal delivery of oxytocin to rabbits using a mucoadhesive buccal patch. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552454/),[ml] / [min],20.4,31739,DB00107,Oxytocin
,9552454,steady-state plasma OT concentration (Css),The steady-state plasma OT concentration (Css) following application of the buccal patches was 80.6 +/- 15.9 pg/ml.,Transmucosal delivery of oxytocin to rabbits using a mucoadhesive buccal patch. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552454/),[pg] / [ml],80.6,31740,DB00107,Oxytocin
,9552454,lag-time,The lag-time associated with attainment of the Css was 0.45 +/- 0.18 hr.,Transmucosal delivery of oxytocin to rabbits using a mucoadhesive buccal patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552454/),h,0.45,31741,DB00107,Oxytocin
,9552454,Steady-state flux (Jss),Steady-state flux (Jss) of oxytocin in vivo was 139 +/- 36.8 ng/hr/cm2.,Transmucosal delivery of oxytocin to rabbits using a mucoadhesive buccal patch. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552454/),[ng] / [cm2·h],139,31742,DB00107,Oxytocin
,9552454,bioavailability,"Based on the amount of OT remaining in the patches following removal, the average dose of OT released in vivo was 0.27 +/- 0.024 mg with a bioavailability of 0.1%.",Transmucosal delivery of oxytocin to rabbits using a mucoadhesive buccal patch. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552454/),%,0.1,31743,DB00107,Oxytocin
,9321512,t1/2,"After iv dosing at 1, 2.5, and 10 mg/kg, the compound had a t1/2 of approximately 2 hr and plasma clearance between 23 and 36 ml/min/kg at all doses and in both species.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),h,2,38144,DB00107,Oxytocin
,9321512,plasma clearance,"After iv dosing at 1, 2.5, and 10 mg/kg, the compound had a t1/2 of approximately 2 hr and plasma clearance between 23 and 36 ml/min/kg at all doses and in both species.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),[ml] / [kg·min],23 and 36,38145,DB00107,Oxytocin
,9321512,plasma clearance,The exception was female rats at the 10 mg/kg dose where plasma clearance decreased to 18 ml/min/kg.,"Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),[ml] / [kg·min],18,38146,DB00107,Oxytocin
,9321512,Vdss,The Vdss was between 2.0 and 2.6 liters/kg for rats and 3.4 to 4.9 liters/kg for dogs.,"Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),[l] / [kg],2.0 and 2.6,38147,DB00107,Oxytocin
,9321512,Vdss,The Vdss was between 2.0 and 2.6 liters/kg for rats and 3.4 to 4.9 liters/kg for dogs.,"Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),[l] / [kg],3.4 to 4.9,38148,DB00107,Oxytocin
<,9321512,Cmax,Mean Cmax values were achieved at <1 hr at the low doses (25 mg/kg in rats and 5 mg/kg in dogs) and between 1 and 4 hr at the higher doses (100 mg/kg in rats and 33 mg/kg in dogs).,"Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),h,1,38149,DB00107,Oxytocin
,9321512,Cmax,Mean Cmax values were achieved at <1 hr at the low doses (25 mg/kg in rats and 5 mg/kg in dogs) and between 1 and 4 hr at the higher doses (100 mg/kg in rats and 33 mg/kg in dogs).,"Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),h,1 and 4,38150,DB00107,Oxytocin
,9321512,Oral bioavailability,"Oral bioavailability was estimated at 14% and 18% for the 5 mg/kg dose in female and male rats, respectively, 41% for the 25 mg/kg dose in male rats and 17% and 41%, respectively, for the 5 and 33 mg/kg doses in dogs.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),%,14,38151,DB00107,Oxytocin
,9321512,Oral bioavailability,"Oral bioavailability was estimated at 14% and 18% for the 5 mg/kg dose in female and male rats, respectively, 41% for the 25 mg/kg dose in male rats and 17% and 41%, respectively, for the 5 and 33 mg/kg doses in dogs.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),%,18,38152,DB00107,Oxytocin
,9321512,Oral bioavailability,"Oral bioavailability was estimated at 14% and 18% for the 5 mg/kg dose in female and male rats, respectively, 41% for the 25 mg/kg dose in male rats and 17% and 41%, respectively, for the 5 and 33 mg/kg doses in dogs.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),%,41,38153,DB00107,Oxytocin
,9321512,Oral bioavailability,"Oral bioavailability was estimated at 14% and 18% for the 5 mg/kg dose in female and male rats, respectively, 41% for the 25 mg/kg dose in male rats and 17% and 41%, respectively, for the 5 and 33 mg/kg doses in dogs.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),%,17,38154,DB00107,Oxytocin
,5824107,half-life,"The median half-life of oxytocin after a single injection of 2 u. was 3.2 min (2.0-5.7, 95% confidence limits); this increased significantly (P < 0.01) to 4.8 min (4.4-6.1) when the hormone was infused at a rate of 500 m-u./min.","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),min,3.2,46590,DB00107,Oxytocin
,5824107,half-life,"The median half-life of oxytocin after a single injection of 2 u. was 3.2 min (2.0-5.7, 95% confidence limits); this increased significantly (P < 0.01) to 4.8 min (4.4-6.1) when the hormone was infused at a rate of 500 m-u./min.","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),min,4.8,46591,DB00107,Oxytocin
,5824107,half-life,"8-lysine vasopressin (LVP), the half-life was 5.7 min (3.6-6.0).","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),min,5.7,46592,DB00107,Oxytocin
,5824107,half-lives,"Continuous infusions of the hormones at a rate of 120 m-u./min yielded half-lives of 5.5 min (5.0-7.1) for LVP, and 5.6 min (3.9-9.5) for 8-arginine vasopressin (AVP).","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),min,5.5,46593,DB00107,Oxytocin
,5824107,half-lives,"Continuous infusions of the hormones at a rate of 120 m-u./min yielded half-lives of 5.5 min (5.0-7.1) for LVP, and 5.6 min (3.9-9.5) for 8-arginine vasopressin (AVP).","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),min,5.6,46594,DB00107,Oxytocin
,5824107,clearance,"In accordance with its shorter half-life, the clearance of oxytocin was greater than that of the vasopressins (1.5 l./min, compared with 1.0 l./min).","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),[l] / [min],1.5,46595,DB00107,Oxytocin
,5824107,clearance,"In accordance with its shorter half-life, the clearance of oxytocin was greater than that of the vasopressins (1.5 l./min, compared with 1.0 l./min).","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),[l] / [min],1.0,46596,DB00107,Oxytocin
,10454085,half-life,"Neither dose of oxytocin nor day of treatment affected the half-life of the exogenous oxytocin, which was determined to be 6.8 min.",PGFM response to exogenous oxytocin and determination of the half-life of oxytocin in nonpregnant mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454085/),min,6.8,47953,DB00107,Oxytocin
,7573268,steady-state plasma concentrations,"The average steady-state plasma concentrations of patients receiving intravenous atosiban were 442 +/- 73 ng/ml (mean +/- SD), with steady state achieved by 1 hour after the start of the infusion.",The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7573268/),[ng] / [ml],442,50180,DB00107,Oxytocin
,7573268,initial,"After the completion of the infusion, plasma concentrations declined rapidly in a biexponential manner with initial and terminal half-life estimates of 13 +/- 3 and 102 +/- 18 minutes, respectively.",The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7573268/),min,13,50181,DB00107,Oxytocin
,7573268,terminal half-life,"After the completion of the infusion, plasma concentrations declined rapidly in a biexponential manner with initial and terminal half-life estimates of 13 +/- 3 and 102 +/- 18 minutes, respectively.",The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7573268/),min,102,50182,DB00107,Oxytocin
,7573268,effective half-life,The effective half-life was 18 +/- 3 minutes.,The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7573268/),min,18,50183,DB00107,Oxytocin
,7573268,plasma clearance,The plasma clearance of atosiban was relatively high (42 L/hr) and the volume of distribution (approximately 18 L) was consistent with distribution into extracellular fluid.,The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7573268/),[l] / [h],42,50184,DB00107,Oxytocin
,7573268,volume of distribution,The plasma clearance of atosiban was relatively high (42 L/hr) and the volume of distribution (approximately 18 L) was consistent with distribution into extracellular fluid.,The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7573268/),l,18,50185,DB00107,Oxytocin
,31830691,maximum concentration (CMAX),"Pharmacokinetic parameters, determined by PKSolver excel add-in, demonstrated an average maximum concentration (CMAX) of 63.3 pg/mL at 3.5 min after intranasal dose administration.",Short communication: pharmacokinetics of oxytocin administered intranasally to beef cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31830691/),[pg] / [ml],63.3,66120,DB00107,Oxytocin
,31830691,half-life (T1/2),An average half-life (T1/2) of 12.1 min after intranasal administration was determined.,Short communication: pharmacokinetics of oxytocin administered intranasally to beef cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31830691/),min,12.1,66121,DB00107,Oxytocin
,22538009,half-life,"The half-life of oxytocin was determined to be 5.89 min, the clearance rate 11.67 L/min, mean residence time (MRT) 7.78 min.",Ex vivo influence of carbetocin on equine myometrial muscles and comparison with oxytocin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538009/),min,5.89,83669,DB00107,Oxytocin
,22538009,clearance rate,"The half-life of oxytocin was determined to be 5.89 min, the clearance rate 11.67 L/min, mean residence time (MRT) 7.78 min.",Ex vivo influence of carbetocin on equine myometrial muscles and comparison with oxytocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538009/),[l] / [min],11.67,83670,DB00107,Oxytocin
,22538009,mean residence time (MRT),"The half-life of oxytocin was determined to be 5.89 min, the clearance rate 11.67 L/min, mean residence time (MRT) 7.78 min.",Ex vivo influence of carbetocin on equine myometrial muscles and comparison with oxytocin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538009/),min,7.78,83671,DB00107,Oxytocin
,22538009,effective plasma concentration,The effective plasma concentration was estimated to be 0.25 ng/mL.,Ex vivo influence of carbetocin on equine myometrial muscles and comparison with oxytocin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538009/),[ng] / [ml],0.25,83672,DB00107,Oxytocin
,22538009,maximum effect (EC(50)),This was similar to the concentration achieved for the organ bath study where the concentration that produced 50% of the maximum effect (EC(50)) was calculated at 0.45 ng/mL.,Ex vivo influence of carbetocin on equine myometrial muscles and comparison with oxytocin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538009/),[ng] / [ml],0.45,83673,DB00107,Oxytocin
>,16250654,pK(i),Varying the functionality and substitution pattern of substituents in the 7-aryl ring and varying the chirality of this exocyclic ring have produced potent oxytocin antagonists (pK(i) > 8.5).,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16250654/),,8.5,91938,DB00107,Oxytocin
,16250654,bioavailability,It has good bioavailability (46%) in the rat and moderate bioavailability (13-31%) in the dog and is more active in vivo in the rat than atosiban (rat DR(10) = 0.44 mg/kg iv).,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16250654/),%,46,91939,DB00107,Oxytocin
,16250654,bioavailability,It has good bioavailability (46%) in the rat and moderate bioavailability (13-31%) in the dog and is more active in vivo in the rat than atosiban (rat DR(10) = 0.44 mg/kg iv).,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16250654/),%,13-31,91940,DB00107,Oxytocin
,19165935,half-life,Administration of carbetocin was well tolerated by all horses and its half-life was 17.2 min.,"Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, following intravenous administration in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19165935/),min,17.2,95615,DB00107,Oxytocin
,19165935,half-life,The half-life of carbetocin is greater than that previously reported for oxytocin (6.8 min).,"Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, following intravenous administration in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19165935/),min,6.8,95616,DB00107,Oxytocin
,28679021,clearance,"The clearance, volume of distribution at steady state, distribution half-life, and terminal half-life were estimated to be 27 L/h, 15 L, 5.5 minutes, and 1.2 hours, respectively.",Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28679021/),[l] / [h],27,95634,DB00107,Oxytocin
,28679021,distribution half-life,"The clearance, volume of distribution at steady state, distribution half-life, and terminal half-life were estimated to be 27 L/h, 15 L, 5.5 minutes, and 1.2 hours, respectively.",Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28679021/),l,15,95635,DB00107,Oxytocin
,28679021,distribution half-life,"The clearance, volume of distribution at steady state, distribution half-life, and terminal half-life were estimated to be 27 L/h, 15 L, 5.5 minutes, and 1.2 hours, respectively.",Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28679021/),min,5.5,95636,DB00107,Oxytocin
,28679021,terminal half-life,"The clearance, volume of distribution at steady state, distribution half-life, and terminal half-life were estimated to be 27 L/h, 15 L, 5.5 minutes, and 1.2 hours, respectively.",Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28679021/),h,1.2,95637,DB00107,Oxytocin
,28679021,bioavailability,"The bioavailability following vaginal administration was estimated to be 2.5% for the typical patient, but with considerable variability both between individuals (interindividual variability of 374%) and between occasions (interoccasion variability of 79%).",Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28679021/),%,2.5,95638,DB00107,Oxytocin
,6486188,plasma clearance rate,"The results demonstrated: the [OT]p rises linearly with each dose for the first 40 minutes of the infusion; there is no difference between the 40- and 60-minute sample values, suggesting that the peak [OT]p of each dose is achieved in 40 minutes; the increment in [OT]p required to produce effective contractility varies widely from 0.58 to 5.09 microU/ml; the plasma clearance rate varied from 11.2 to 32.5 ml/kg/min.",Oxytocin augmentation of dysfunctional labor. IV. Oxytocin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486188/),[ml] / [kg·min],11.2 to 32.5,97036,DB00107,Oxytocin
,7443113,MCR,OT MCR was 27 +/- 1.8 ml/kg/min in men; 20.6 +/- 2.8 ml/kf/min in nonpregnant women; and 23.1 +/- 2.6 ml/kg/min in pregnant women.,Pharmacokinetics of oxytocin in the human subject. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7443113/),[ml] / [kg·min],27,98901,DB00107,Oxytocin
,7443113,MCR,OT MCR was 27 +/- 1.8 ml/kg/min in men; 20.6 +/- 2.8 ml/kf/min in nonpregnant women; and 23.1 +/- 2.6 ml/kg/min in pregnant women.,Pharmacokinetics of oxytocin in the human subject. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7443113/),[ml] / [kf·min],20.6,98902,DB00107,Oxytocin
,7443113,MCR,OT MCR was 27 +/- 1.8 ml/kg/min in men; 20.6 +/- 2.8 ml/kf/min in nonpregnant women; and 23.1 +/- 2.6 ml/kg/min in pregnant women.,Pharmacokinetics of oxytocin in the human subject. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7443113/),[ml] / [kg·min],23.1,98903,DB00107,Oxytocin
,7443113,MCR,The OT MCR corrected to prepregnancy weight was 25.4 +/- 2.0 ml/kg/min.,Pharmacokinetics of oxytocin in the human subject. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7443113/),[ml] / [kg·min],25.4,98904,DB00107,Oxytocin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],62.0,99353,DB00107,Oxytocin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],163.7,99354,DB00107,Oxytocin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],468.0,99355,DB00107,Oxytocin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],34.4,99356,DB00107,Oxytocin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],116.7,99357,DB00107,Oxytocin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],418.0,99358,DB00107,Oxytocin
,14678081,Tmax,Tmax was observed at about 1 h.,Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),h,1,99359,DB00107,Oxytocin
,3751461,total body clearance,"When given intravenously as bolus injection (10 nmol/kg/body weight), the total body clearance amounted to 0.623 +/- 0.099 (SEM) l/h kg and the half-life to 16.2 +/- 2.4 min.",Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751461/),[l] / [h·kg],0.623,114500,DB00107,Oxytocin
,3751461,half-life,"When given intravenously as bolus injection (10 nmol/kg/body weight), the total body clearance amounted to 0.623 +/- 0.099 (SEM) l/h kg and the half-life to 16.2 +/- 2.4 min.",Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751461/),min,16.2,114501,DB00107,Oxytocin
,3751461,bioavailability,"After intranasal administration (100 nmol/kg/body weight), the bioavailability was 10.5 +/- 2.9%.",Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751461/),%,10.5,114502,DB00107,Oxytocin
,30341006,time to Cmax,"Food decreased the rate of absorption for all 3 formulations (median time to Cmax 3-6 hours compared to 1-2 hours fasted) but increased the extent of absorption (Cmax and AUC0-∞ increased by 75-149% and 33-49%, respectively).","Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30341006/),h,3-6,117172,DB00107,Oxytocin
,30341006,time to Cmax,"Food decreased the rate of absorption for all 3 formulations (median time to Cmax 3-6 hours compared to 1-2 hours fasted) but increased the extent of absorption (Cmax and AUC0-∞ increased by 75-149% and 33-49%, respectively).","Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30341006/),h,1-2,117173,DB00107,Oxytocin
,9612235,metabolic clearance rate,"The metabolic clearance rate of OT as determined during the bolus trials (n = 7) was 22.2 +/- 1.5 ml.min-1.kg-1 in pregnancy and 16.3 +/- 1.4 ml.min-1.kg-1 postpartum (P < 0.05), respectively, and 23.7 +/- 2.8 vs.",Effect of pregnancy on the metabolic clearance rate and the volume of distribution of oxytocin in the baboon. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612235/),[ml] / [kg·min],22.2,120480,DB00107,Oxytocin
,9612235,metabolic clearance rate,"The metabolic clearance rate of OT as determined during the bolus trials (n = 7) was 22.2 +/- 1.5 ml.min-1.kg-1 in pregnancy and 16.3 +/- 1.4 ml.min-1.kg-1 postpartum (P < 0.05), respectively, and 23.7 +/- 2.8 vs.",Effect of pregnancy on the metabolic clearance rate and the volume of distribution of oxytocin in the baboon. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612235/),[ml] / [kg·min],16.3,120481,DB00107,Oxytocin
,9612235,metabolic clearance rate,"The metabolic clearance rate of OT as determined during the bolus trials (n = 7) was 22.2 +/- 1.5 ml.min-1.kg-1 in pregnancy and 16.3 +/- 1.4 ml.min-1.kg-1 postpartum (P < 0.05), respectively, and 23.7 +/- 2.8 vs.",Effect of pregnancy on the metabolic clearance rate and the volume of distribution of oxytocin in the baboon. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612235/),,23.7,120482,DB00107,Oxytocin
,9612235,mean residence time (MRT),"The mean residence time (MRT) of OT was shorter during pregnancy, 7.7 +/- 0.8 vs. 10.8 +/- 1.2 min postpartum (P < 0.05).",Effect of pregnancy on the metabolic clearance rate and the volume of distribution of oxytocin in the baboon. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612235/),min,7.7,120483,DB00107,Oxytocin
,9612235,mean residence time (MRT),"The mean residence time (MRT) of OT was shorter during pregnancy, 7.7 +/- 0.8 vs. 10.8 +/- 1.2 min postpartum (P < 0.05).",Effect of pregnancy on the metabolic clearance rate and the volume of distribution of oxytocin in the baboon. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612235/),min,10.8,120484,DB00107,Oxytocin
,28317126,peak serum concentrations,Mean (±SD) peak serum concentrations of DCA were 3.97 ± 0.50 μg/ml (low dose) and 7.45 ± 1.05 μg/ml (high dose).,Pharmacokinetics of ceftiofur sodium in equine pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317126/),[μg] / [ml],3.97,129571,DB00107,Oxytocin
,28317126,peak serum concentrations,Mean (±SD) peak serum concentrations of DCA were 3.97 ± 0.50 μg/ml (low dose) and 7.45 ± 1.05 μg/ml (high dose).,Pharmacokinetics of ceftiofur sodium in equine pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317126/),[μg] / [ml],7.45,129572,DB00107,Oxytocin
,28317126,Terminal half-life,Terminal half-life was significantly (p = .014) shorter after administration of the low dose (2.91 ± 0.59 hr) than after administration of the high dose (4.10 ± 0.72 hr).,Pharmacokinetics of ceftiofur sodium in equine pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317126/),h,2.91,129573,DB00107,Oxytocin
,28317126,Terminal half-life,Terminal half-life was significantly (p = .014) shorter after administration of the low dose (2.91 ± 0.59 hr) than after administration of the high dose (4.10 ± 0.72 hr).,Pharmacokinetics of ceftiofur sodium in equine pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317126/),h,4.10,129574,DB00107,Oxytocin
,28317126,serum concentration,The mean serum concentration of DCA from mares at time of foaling was 7.96 ± 1.39 μg/ml.,Pharmacokinetics of ceftiofur sodium in equine pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317126/),[μg] / [ml],7.96,129575,DB00107,Oxytocin
,8355953,area under the curve (AUC),"For plasma, the mean (+/- standard deviation) area under the curve (AUC) of carbetocin versus time was 1119.3 +/- 315.9 pg/mL, a value about 50 times higher than the mean AUC for carbetocin in breast milk (18.6 +/- 13.7 and 29.0 +/- 23.8 pg/mL for the right and left breast, respectively).",Transfer of carbetocin into human breast milk. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355953/),[pg] / [ml],1119.3,131717,DB00107,Oxytocin
,8355953,AUC,"For plasma, the mean (+/- standard deviation) area under the curve (AUC) of carbetocin versus time was 1119.3 +/- 315.9 pg/mL, a value about 50 times higher than the mean AUC for carbetocin in breast milk (18.6 +/- 13.7 and 29.0 +/- 23.8 pg/mL for the right and left breast, respectively).",Transfer of carbetocin into human breast milk. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355953/),[pg] / [ml],18.6,131718,DB00107,Oxytocin
,8355953,AUC,"For plasma, the mean (+/- standard deviation) area under the curve (AUC) of carbetocin versus time was 1119.3 +/- 315.9 pg/mL, a value about 50 times higher than the mean AUC for carbetocin in breast milk (18.6 +/- 13.7 and 29.0 +/- 23.8 pg/mL for the right and left breast, respectively).",Transfer of carbetocin into human breast milk. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355953/),[pg] / [ml],29.0,131719,DB00107,Oxytocin
,8355953,ratio of milk to plasma AUC,"The ratio of milk to plasma AUC was low: 1.7 +/- 0.9 and 3.1 +/- 2.8% for the left and right breast, respectively.",Transfer of carbetocin into human breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355953/),,1,131720,DB00107,Oxytocin
,8355953,ratio of milk to plasma AUC,"The ratio of milk to plasma AUC was low: 1.7 +/- 0.9 and 3.1 +/- 2.8% for the left and right breast, respectively.",Transfer of carbetocin into human breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355953/),,3.1,131721,DB00107,Oxytocin
,19183510,systemic clearance (CLT,"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),[l] / [kg·min],0.0624,143983,DB00107,Oxytocin
,19183510,systemic clearance (CLT,"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),,0.0622,143984,DB00107,Oxytocin
,19183510,central compartment volume of distribution (VC,"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),[l] / [kg],0.7906,143985,DB00107,Oxytocin
,19183510,central compartment volume of distribution (VC,"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),,0.6961,143986,DB00107,Oxytocin
,19183510,elimination half life (t(1/2),"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),min,7.94,143987,DB00107,Oxytocin
,19183510,elimination half life (t(1/2),"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),,9.08,143988,DB00107,Oxytocin
,19183510,CLT,"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),[l] / [kg·min],0.0266,143989,DB00107,Oxytocin
,19183510,CLT,"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),,0.0284,143990,DB00107,Oxytocin
,19183510,VC,"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),[l] / [kg],0.2213,143991,DB00107,Oxytocin
,19183510,VC,"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),,0.2227,143992,DB00107,Oxytocin
,19183510,t(1/2),"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),min,21.09,143993,DB00107,Oxytocin
,19183510,t(1/2),"At doses up to 500 ng/kg, OT showed a higher median systemic clearance (CLT = 0.0624 L/(min*kg); 0.0622 +/- 0.0228 as mean +/- SD value), a higher median central compartment volume of distribution (VC = 0.7906 L/kg; 0.6961 +/- 0.1754), and a lower median elimination half life (t(1/2)(lambdaz) 7.94 min; 9.08 +/- 4.3) with respect to the higher doses (CLT = 0.0266 L/(min*kg); 0.0284 +/- 0.0098, VC = 0.2213 L/kg; 0.2227 +/- 0.1142, and t(1/2)(lambdaz) 21.09 min; 28.36 +/- 21.8), all differences being significant (p 0.0008).",Evidence for non-linear pharmacokinetics of oxytocin in anesthetizetized rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19183510/),,28.36,143994,DB00107,Oxytocin
,29435767,maximum concentrations,"The maximum concentrations for SL and intramuscular doses in anesthetized pigs were 207 and 612 pg/mL, respectively.",Heat-stable sublingual oxytocin tablets as a potential needle-free approach for preventing postpartum hemorrhage in low-resource settings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29435767/),[pg] / [ml],207,149470,DB00107,Oxytocin
,29435767,maximum concentrations,"The maximum concentrations for SL and intramuscular doses in anesthetized pigs were 207 and 612 pg/mL, respectively.",Heat-stable sublingual oxytocin tablets as a potential needle-free approach for preventing postpartum hemorrhage in low-resource settings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29435767/),[pg] / [ml],612,149471,DB00107,Oxytocin
,6693537,MCR,"The mean OT MCR in these women was 17.4 +/- 9.2 (+/- SEM) ml/kg X min, similar to the MCR in normal men (17.6 +/- 2.1 ml/kg X min).",Studies of oxytocin in plasma of women during hypocontractile labor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6693537/),[ml] / [kg·min],17.4,155798,DB00107,Oxytocin
,6693537,MCR,"The mean OT MCR in these women was 17.4 +/- 9.2 (+/- SEM) ml/kg X min, similar to the MCR in normal men (17.6 +/- 2.1 ml/kg X min).",Studies of oxytocin in plasma of women during hypocontractile labor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6693537/),[ml] / [kg·min],17.6,155799,DB00107,Oxytocin
,12660315,IC50,Compound 1 inhibits oxytocin-evoked intracellular Ca2+ mobilization (IC50 = 8 nM).,"Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12660315/),nM,8,191830,DB00107,Oxytocin
,12660315,pA2,Oxytocininduced contraction of isolated rat uterine strips is blocked by compound 1 (pA2 = 7.82).,"Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12660315/),,7.82,191831,DB00107,Oxytocin
,12660315,ED50,"In anesthetized nonpregnant rats, single administration of compound 1 by i.v. or oral routes causes dose-dependent inhibition of contractions elicited by repeated injections of oxytocin with ED50 = 3.5 mg/kg i.v. and 89 mg/kg p.o., respectively.","Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12660315/),[mg] / [kg],3.5,191832,DB00107,Oxytocin
,12660315,ED50,"In anesthetized nonpregnant rats, single administration of compound 1 by i.v. or oral routes causes dose-dependent inhibition of contractions elicited by repeated injections of oxytocin with ED50 = 3.5 mg/kg i.v. and 89 mg/kg p.o., respectively.","Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12660315/),[mg] / [kg],89,191833,DB00107,Oxytocin
,12527084,area under the curve (AUC),"Calculation of the area under the curve (AUC) for progesterone secretion from Day 7 to Day 12 also revealed a significant decrease in progesterone secretion in the dilatation group (dilatation: 34.1+/-7.3, insertion: 35.6+/-7.8, control: 39.1+/-5.9 ng/ml; P<0.05).",Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[ng] / [ml],34.1,192157,DB00107,Oxytocin
,12527084,area under the curve (AUC),"Calculation of the area under the curve (AUC) for progesterone secretion from Day 7 to Day 12 also revealed a significant decrease in progesterone secretion in the dilatation group (dilatation: 34.1+/-7.3, insertion: 35.6+/-7.8, control: 39.1+/-5.9 ng/ml; P<0.05).",Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[ng] / [ml],35.6,192158,DB00107,Oxytocin
,12527084,area under the curve (AUC),"Calculation of the area under the curve (AUC) for progesterone secretion from Day 7 to Day 12 also revealed a significant decrease in progesterone secretion in the dilatation group (dilatation: 34.1+/-7.3, insertion: 35.6+/-7.8, control: 39.1+/-5.9 ng/ml; P<0.05).",Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[ng] / [ml],39.1,192159,DB00107,Oxytocin
,12527084,maximum peaks,Cervical insertion and dilatation caused a rapid and pronounced increase in plasma concentrations of oxytocin from basal levels (1.0-6.1 pg/ml) to maximum peaks (insertion: 125.5 pg/ml and dilatation: 305.2 pg/ml).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [ml],125.5,192160,DB00107,Oxytocin
,12527084,maximum peaks,Cervical insertion and dilatation caused a rapid and pronounced increase in plasma concentrations of oxytocin from basal levels (1.0-6.1 pg/ml) to maximum peaks (insertion: 125.5 pg/ml and dilatation: 305.2 pg/ml).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [ml],305.2,192161,DB00107,Oxytocin
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],858.4,192162,DB00107,Oxytocin
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],411.9,192163,DB00107,Oxytocin
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],1697,192164,DB00107,Oxytocin
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],1078.5,192165,DB00107,Oxytocin
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],186,192166,DB00107,Oxytocin
,12527084,AUC,The AUC for oxytocin was significantly higher after insertion (Day 5: 858.4+/-469.9; Day 7: 411.9+/-213 pg/ml/h) and dilatation (Day 5: 1697+/-1725; Day 7: 1078.5+/-764 pg/ml/h) when compared to controls (Day 5: 186+/-98; Day 7: 156+/-23.5 pg/ml/h; P<0.05).,Secretion patterns of oxytocin and PGF2alpha-metabolite in response to cervical dilatation in cyclic mares. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12527084/),[pg] / [h·ml],156,192167,DB00107,Oxytocin
,9622556,Ki,"The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors.","Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622556/),nM,4.1,199232,DB00107,Oxytocin
,9622556,AD50,"The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors.","Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622556/),[mg] / [kg],0.71,199233,DB00107,Oxytocin
,9622556,oral bioavailability,"The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors.","Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622556/),%,90,199234,DB00107,Oxytocin
,9622556,oral bioavailability,"The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors.","Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622556/),%,96,199235,DB00107,Oxytocin
>,9622556,solubility,"The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors.","Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622556/),[mg] / [ml],8.5,199236,DB00107,Oxytocin
>,15671092,duration of action,"Barusiban also had a much longer duration of action (>13-15 h, compared with 1-3 h for atosiban).","Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671092/),h,13-15,200343,DB00107,Oxytocin
,15671092,duration of action,"Barusiban also had a much longer duration of action (>13-15 h, compared with 1-3 h for atosiban).","Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671092/),h,1-3,200344,DB00107,Oxytocin
,3942702,duration of effect,The duration of effect was also greatest with that analogue (40-50 min).,Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942702/),min,40-50,200730,DB00107,Oxytocin
,3942702,plasma half-life,Pharmacokinetic studies of intravenous dE-TVT (10 ng/kg body weight) showed that the plasma half-life was approximately 16 min and the clearance 30 l/h.,Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942702/),min,16,200731,DB00107,Oxytocin
,3942702,clearance,Pharmacokinetic studies of intravenous dE-TVT (10 ng/kg body weight) showed that the plasma half-life was approximately 16 min and the clearance 30 l/h.,Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942702/),[l] / [h],30,200732,DB00107,Oxytocin
,3942702,bioavailability,The bioavailability of 100 ng/kg given intranasally was about 5.5%.,Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942702/),%,5.5,200733,DB00107,Oxytocin
,15200183,elimination half-life,The elimination half-life of ropivacaine was significantly less than that of bupivacaine (5.2 +/- 0.7 h vs. 10.8 +/- 1.06 h).,[Clinical effects and pharmacokinetics of ropivacaine and bupivacaine for epidural analgesia during labor]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200183/),h,5.2,205076,DB00107,Oxytocin
,15200183,elimination half-life,The elimination half-life of ropivacaine was significantly less than that of bupivacaine (5.2 +/- 0.7 h vs. 10.8 +/- 1.06 h).,[Clinical effects and pharmacokinetics of ropivacaine and bupivacaine for epidural analgesia during labor]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200183/),h,10.8,205077,DB00107,Oxytocin
,8568623,distribution half-life,"The distribution half-life was 0.049 +/- 0.106 h, the elimination half-life was 0.33 +/- 0.23 h, the total body clearance was 67.1 +/- 13.4 L h-1 and the volume of distribution was 33.2 +/- 28.1 L.",Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568623/),h,0.049,217752,DB00107,Oxytocin
,8568623,elimination half-life,"The distribution half-life was 0.049 +/- 0.106 h, the elimination half-life was 0.33 +/- 0.23 h, the total body clearance was 67.1 +/- 13.4 L h-1 and the volume of distribution was 33.2 +/- 28.1 L.",Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568623/),h,0.33,217753,DB00107,Oxytocin
,8568623,total body clearance,"The distribution half-life was 0.049 +/- 0.106 h, the elimination half-life was 0.33 +/- 0.23 h, the total body clearance was 67.1 +/- 13.4 L h-1 and the volume of distribution was 33.2 +/- 28.1 L.",Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568623/),[l] / [h],67.1,217754,DB00107,Oxytocin
,8568623,volume of distribution,"The distribution half-life was 0.049 +/- 0.106 h, the elimination half-life was 0.33 +/- 0.23 h, the total body clearance was 67.1 +/- 13.4 L h-1 and the volume of distribution was 33.2 +/- 28.1 L.",Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568623/),l,33.2,217755,DB00107,Oxytocin
,8568623,bioavailability,"After sublingual administration, a poor bioavailability with a 10-fold variation between 0.007 and 0.07% was observed.",Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568623/),%,0.007,217756,DB00107,Oxytocin
,8568623,lag time,The lag time was subject-dependent and ranged between 0.12 and 0.30 h (40% CV).,Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568623/),h,0.12 and 0.30,217757,DB00107,Oxytocin
,8568623,absorption half-life,"The absorption half-life was 0.45 +/- 0.29 h, and the apparent elimination half-life 0.69 +/ - 0.26 h.",Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568623/),h,0.45,217758,DB00107,Oxytocin
,8568623,apparent elimination half-life,"The absorption half-life was 0.45 +/- 0.29 h, and the apparent elimination half-life 0.69 +/ - 0.26 h.",Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568623/),h,0.69,217759,DB00107,Oxytocin
,8238146,t1/2 alpha,Maternal plasma levels of atosiban reached a maximum of 585.2 +/- 82.2 (ng/ml mean +/- SD) at the end of the infusion and decreased biexponentially with a mean t1/2 alpha of 17 minutes and a mean t1/2 beta of 2.2 hours.,Maternal and fetal cardiovascular effects and placental transfer of the oxytocin antagonist atosiban in late-gestation pregnant sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8238146/),min,17,219319,DB00107,Oxytocin
,8238146,t1/2 beta,Maternal plasma levels of atosiban reached a maximum of 585.2 +/- 82.2 (ng/ml mean +/- SD) at the end of the infusion and decreased biexponentially with a mean t1/2 alpha of 17 minutes and a mean t1/2 beta of 2.2 hours.,Maternal and fetal cardiovascular effects and placental transfer of the oxytocin antagonist atosiban in late-gestation pregnant sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8238146/),h,2.2,219320,DB00107,Oxytocin
,18468385,flow rate,"In vivo studies on anaesthetized New Zealand albino male rabbits were conducted and drug levels in plasma were estimated at 220 nm by reverse phase HPLC using BDS Hypersil C8 column using acetonitrile and 0.05 M potassium dihydrogen orthophosphate buffer pH 6.6 (20:80 v/v) as mobile phase, at a flow rate of 1.25 mL/ min.",In vitro and in vivo evaluation of a novel mucoadhesive buccal oxytocin tablet prepared with Dillenia indica fruit mucilage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468385/),[ml] / [min],1.25,219495,DB00107,Oxytocin
,18468385,C(max),"Optimized formulation showed C(max), T(max), t1/2 and AUC(total), 688 pg/mL, 2 h, 0.079 h, and 1999.72 h x pg/mL respectively.",In vitro and in vivo evaluation of a novel mucoadhesive buccal oxytocin tablet prepared with Dillenia indica fruit mucilage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468385/),[pg] / [ml],688,219496,DB00107,Oxytocin
,18468385,T(max),"Optimized formulation showed C(max), T(max), t1/2 and AUC(total), 688 pg/mL, 2 h, 0.079 h, and 1999.72 h x pg/mL respectively.",In vitro and in vivo evaluation of a novel mucoadhesive buccal oxytocin tablet prepared with Dillenia indica fruit mucilage. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468385/),h,2,219497,DB00107,Oxytocin
,18468385,T(max),"Optimized formulation showed C(max), T(max), t1/2 and AUC(total), 688 pg/mL, 2 h, 0.079 h, and 1999.72 h x pg/mL respectively.",In vitro and in vivo evaluation of a novel mucoadhesive buccal oxytocin tablet prepared with Dillenia indica fruit mucilage. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468385/),h,0.079,219498,DB00107,Oxytocin
,18468385,t1/2,"Optimized formulation showed C(max), T(max), t1/2 and AUC(total), 688 pg/mL, 2 h, 0.079 h, and 1999.72 h x pg/mL respectively.",In vitro and in vivo evaluation of a novel mucoadhesive buccal oxytocin tablet prepared with Dillenia indica fruit mucilage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468385/),h,2,219499,DB00107,Oxytocin
,18468385,t1/2,"Optimized formulation showed C(max), T(max), t1/2 and AUC(total), 688 pg/mL, 2 h, 0.079 h, and 1999.72 h x pg/mL respectively.",In vitro and in vivo evaluation of a novel mucoadhesive buccal oxytocin tablet prepared with Dillenia indica fruit mucilage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468385/),h,0.079,219500,DB00107,Oxytocin
,18468385,AUC(total),"Optimized formulation showed C(max), T(max), t1/2 and AUC(total), 688 pg/mL, 2 h, 0.079 h, and 1999.72 h x pg/mL respectively.",In vitro and in vivo evaluation of a novel mucoadhesive buccal oxytocin tablet prepared with Dillenia indica fruit mucilage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468385/),[h·pg] / [ml],1999.72,219501,DB00107,Oxytocin
,18468385,bioavailability,The NMBT containing 0.75% w/w sodium taurocholate showed 27% bioavailability without damaging the buccal mucosasuggesting its suitability as an alternative to noninvasive administration of oxytocin.,In vitro and in vivo evaluation of a novel mucoadhesive buccal oxytocin tablet prepared with Dillenia indica fruit mucilage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18468385/),%,27,219502,DB00107,Oxytocin
,27194003,Tmax,IN administration of oxytocin resulted in short (5 min) Tmax and good dose linearity in AUC and Cmax over the dose range tested (10-80 IU per animal).,Rapid Absorption of Dry-Powder Intranasal Oxytocin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194003/),min,5,222986,DB00107,Oxytocin
,27194003,relative bioavailability (BA),The relative bioavailability (BA) of IN oxytocin to IM injection was approximately 12%.,Rapid Absorption of Dry-Powder Intranasal Oxytocin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194003/),%,12,222987,DB00107,Oxytocin
,25384080,induction-delivery interval (IDI),"The induction-delivery interval (IDI) was similar (10 h 13 min with high-dose and 11 h 5 min with intermediate-dose; p = 0.237, NS).",Labour induction with an intermediate-dose oxytocin regimen has advantages over a high-dose regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25384080/),h,10,228976,DB00107,Oxytocin
,25384080,induction-delivery interval (IDI),"The induction-delivery interval (IDI) was similar (10 h 13 min with high-dose and 11 h 5 min with intermediate-dose; p = 0.237, NS).",Labour induction with an intermediate-dose oxytocin regimen has advantages over a high-dose regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25384080/),h,11,228977,DB00107,Oxytocin
<,24874785,EC50,"We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly(7)]dOT), 47 (carba-6-[Phe(2),BuGly(7)]dOT), 55 (carba-6-[3-MeBzlGly(7)]dOT), and 57 (carba-1-[4-FBzlGly(7)]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min(-1) kg(-1).","New, potent, and selective peptidic oxytocin receptor agonists. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874785/),nM,0.1,233736,DB00107,Oxytocin
>,24874785,selectivity ratios,"We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly(7)]dOT), 47 (carba-6-[Phe(2),BuGly(7)]dOT), 55 (carba-6-[3-MeBzlGly(7)]dOT), and 57 (carba-1-[4-FBzlGly(7)]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min(-1) kg(-1).","New, potent, and selective peptidic oxytocin receptor agonists. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874785/),,2000,233737,DB00107,Oxytocin
>,24874785,IC50,"We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly(7)]dOT), 47 (carba-6-[Phe(2),BuGly(7)]dOT), 55 (carba-6-[3-MeBzlGly(7)]dOT), and 57 (carba-1-[4-FBzlGly(7)]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min(-1) kg(-1).","New, potent, and selective peptidic oxytocin receptor agonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874785/),nM,500,233738,DB00107,Oxytocin
,24874785,total clearance,"We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly(7)]dOT), 47 (carba-6-[Phe(2),BuGly(7)]dOT), 55 (carba-6-[3-MeBzlGly(7)]dOT), and 57 (carba-1-[4-FBzlGly(7)]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min(-1) kg(-1).","New, potent, and selective peptidic oxytocin receptor agonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874785/),[ml] / [kg·min],60-80,233739,DB00107,Oxytocin
,2035916,elimination rate constant (beta),"The mean +/- SD value for elimination rate constant (beta) for chloramphenicol in 1-day-old foals (0.131 +/- 0.06 h-1) was significantly (P less than 0.005) lower than the value in 3-day-old foals (0.514 +/- 0.156 h-1), and both values were significantly (P less than 0.05) lower than values for beta in 7-, 14-, and 42-day-old foals.",Influence of age on the disposition kinetics of chloramphenicol in equine neonates. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2035916/),1/[h],0.131,233893,DB00107,Oxytocin
,2035916,elimination rate constant (beta),"The mean +/- SD value for elimination rate constant (beta) for chloramphenicol in 1-day-old foals (0.131 +/- 0.06 h-1) was significantly (P less than 0.005) lower than the value in 3-day-old foals (0.514 +/- 0.156 h-1), and both values were significantly (P less than 0.05) lower than values for beta in 7-, 14-, and 42-day-old foals.",Influence of age on the disposition kinetics of chloramphenicol in equine neonates. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2035916/),1/[h],0.514,233894,DB00107,Oxytocin
,2035916,elimination half-time (t1/2 beta),"With increasing age, the increase in the mean value for beta resulted in decrease in the harmonic mean elimination half-time (t1/2 beta) for chloramphenicol, from 5.29 hours in 1-day-old foals to: 1.35 hours in 3-day-old foals; 0.61 hour in 7-day-old foals; 0.51 hour in 14-day-old foals; and 0.34 hour in 42-day-old foals.",Influence of age on the disposition kinetics of chloramphenicol in equine neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2035916/),h,5.29,233895,DB00107,Oxytocin
,2035916,elimination half-time (t1/2 beta),"With increasing age, the increase in the mean value for beta resulted in decrease in the harmonic mean elimination half-time (t1/2 beta) for chloramphenicol, from 5.29 hours in 1-day-old foals to: 1.35 hours in 3-day-old foals; 0.61 hour in 7-day-old foals; 0.51 hour in 14-day-old foals; and 0.34 hour in 42-day-old foals.",Influence of age on the disposition kinetics of chloramphenicol in equine neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2035916/),h,1.35,233896,DB00107,Oxytocin
,2035916,elimination half-time (t1/2 beta),"With increasing age, the increase in the mean value for beta resulted in decrease in the harmonic mean elimination half-time (t1/2 beta) for chloramphenicol, from 5.29 hours in 1-day-old foals to: 1.35 hours in 3-day-old foals; 0.61 hour in 7-day-old foals; 0.51 hour in 14-day-old foals; and 0.34 hour in 42-day-old foals.",Influence of age on the disposition kinetics of chloramphenicol in equine neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2035916/),h,0.61,233897,DB00107,Oxytocin
,2035916,elimination half-time (t1/2 beta),"With increasing age, the increase in the mean value for beta resulted in decrease in the harmonic mean elimination half-time (t1/2 beta) for chloramphenicol, from 5.29 hours in 1-day-old foals to: 1.35 hours in 3-day-old foals; 0.61 hour in 7-day-old foals; 0.51 hour in 14-day-old foals; and 0.34 hour in 42-day-old foals.",Influence of age on the disposition kinetics of chloramphenicol in equine neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2035916/),h,0.51,233898,DB00107,Oxytocin
,2035916,elimination half-time (t1/2 beta),"With increasing age, the increase in the mean value for beta resulted in decrease in the harmonic mean elimination half-time (t1/2 beta) for chloramphenicol, from 5.29 hours in 1-day-old foals to: 1.35 hours in 3-day-old foals; 0.61 hour in 7-day-old foals; 0.51 hour in 14-day-old foals; and 0.34 hour in 42-day-old foals.",Influence of age on the disposition kinetics of chloramphenicol in equine neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2035916/),h,0.34,233899,DB00107,Oxytocin
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,10,234189,DB00107,Oxytocin
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,24--96,234190,DB00107,Oxytocin
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,0.8,234191,DB00107,Oxytocin
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,33,234192,DB00107,Oxytocin
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,1.0,234193,DB00107,Oxytocin
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,42,234194,DB00107,Oxytocin
,3793853,MCR,The mean (+/- SEM) OT MCR was 16.4 +/- 1.7 ml/kg X min and was independent of the rate of infusion.,Clearance studies of oxytocin in humans using radioimmunoassay measurements of the hormone in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793853/),[ml] / [kg·min],16.4,238561,DB00107,Oxytocin
,3793853,minimum detectable level,The minimum detectable level of OT in urine was 0.2 microU/ml (defined as a bound to free ratio of approximately 90%).,Clearance studies of oxytocin in humans using radioimmunoassay measurements of the hormone in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793853/),[μu] / [ml],0.2,238562,DB00107,Oxytocin
,3793853,bound to free ratio,The minimum detectable level of OT in urine was 0.2 microU/ml (defined as a bound to free ratio of approximately 90%).,Clearance studies of oxytocin in humans using radioimmunoassay measurements of the hormone in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793853/),%,90,238563,DB00107,Oxytocin
,3793853,recovery,The mean recovery of OT was 77 +/- 2%.,Clearance studies of oxytocin in humans using radioimmunoassay measurements of the hormone in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793853/),%,77,238564,DB00107,Oxytocin
,3793853,renal clearance,Mean urinary fractional clearance of OT (OT clearance/creatinine clearance) was 3.6% renal clearance of OT (5.5 ml/min or 0.43% of MCR).,Clearance studies of oxytocin in humans using radioimmunoassay measurements of the hormone in plasma and urine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793853/),[ml] / [min],5.5,238565,DB00107,Oxytocin
,25899007,tmax median,Co-administration of OBE001 and betamethasone was well tolerated and resulted in a tmax median delay of 1 h for OBE001 but not for betamethasone.,Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25899007/),h,1,239519,DB00107,Oxytocin
,29338251,initial half-life,"The pharmacokinetics of OXT after intravenous bolus injection to rats followed a two-compartment model, with a rapid initial half-life of 3 min.",Delivery of Oxytocin to the Brain for the Treatment of Autism Spectrum Disorder by Nasal Application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338251/),min,3,245925,DB00107,Oxytocin
,29338251,nasal bioavailability,The nasal bioavailability of OXT was approximately 2%.,Delivery of Oxytocin to the Brain for the Treatment of Autism Spectrum Disorder by Nasal Application. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338251/),%,2,245926,DB00107,Oxytocin
,30612858,terminal half-life,"The terminal half-life was approximately 12 hours, and steady state was achieved by day 3.","Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30612858/),h,12,248728,DB00107,Oxytocin
,30612858,Accumulation ratios,"Accumulation ratios were higher at the lower doses compared with higher doses (2.3 at 100 mg vs 1.1 at 2,400 mg).","Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30612858/),,2.3,248729,DB00107,Oxytocin
,30612858,Accumulation ratios,"Accumulation ratios were higher at the lower doses compared with higher doses (2.3 at 100 mg vs 1.1 at 2,400 mg).","Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30612858/),,1.1,248730,DB00107,Oxytocin
>,22239250,pK(i),SAR studies involving mono- and disubstitution in the 3'-pyridyl ring and variation of the 3-isobutyl group gave potent compounds (pK(i) > 9.0) with good aqueous solubility.,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239250/),,9.0,250128,DB00107,Oxytocin
,22239250,pK(i),"Evaluation of the pharmacokinetic profile in the rat, dog, and cynomolgus monkey of those derivatives with low cynomolgus monkey and human intrinsic clearance gave 2',6'-dimethyl-3'-pyridyl R-sec-butyl morpholine amide Epelsiban (69), a highly potent oxytocin antagonist (pK(i) = 9.9) with >31000-fold selectivity over all three human vasopressin receptors hV1aR, hV2R, and hV1bR, with no significant P450 inhibition.","Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239250/),,9.9,250129,DB00107,Oxytocin
,22239250,bioavailability,"Epelsiban has low levels of intrinsic clearance against the microsomes of four species, good bioavailability (55%) and comparable potency to atosiban in the rat, but is 100-fold more potent than the latter in vitro and was negative in the genotoxicity screens with a satisfactory oral safety profile in female rats.","Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239250/),%,55,250130,DB00107,Oxytocin
,20356809,peak atosiban concentration (C(max)),"Atosiban plasma concentration measured at Day 1 showed mean peak atosiban concentration (C(max)) 0.40, 0.57, 1.95 microg/ml for low, mid and high dose treated animals and mean peak concentration on Day 28 was 0.41, 0.88, 1.31microg/ml on Day 28 for low, mid and high dose treated animals.",Quantitative determination of oxytocin receptor antagonist atosiban in rat plasma by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356809/),[μg] / [ml],0.40,252655,DB00107,Oxytocin
,20356809,peak atosiban concentration (C(max)),"Atosiban plasma concentration measured at Day 1 showed mean peak atosiban concentration (C(max)) 0.40, 0.57, 1.95 microg/ml for low, mid and high dose treated animals and mean peak concentration on Day 28 was 0.41, 0.88, 1.31microg/ml on Day 28 for low, mid and high dose treated animals.",Quantitative determination of oxytocin receptor antagonist atosiban in rat plasma by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356809/),[μg] / [ml],0.57,252656,DB00107,Oxytocin
,20356809,peak atosiban concentration (C(max)),"Atosiban plasma concentration measured at Day 1 showed mean peak atosiban concentration (C(max)) 0.40, 0.57, 1.95 microg/ml for low, mid and high dose treated animals and mean peak concentration on Day 28 was 0.41, 0.88, 1.31microg/ml on Day 28 for low, mid and high dose treated animals.",Quantitative determination of oxytocin receptor antagonist atosiban in rat plasma by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356809/),[μg] / [ml],1.95,252657,DB00107,Oxytocin
,20356809,peak concentration,"Atosiban plasma concentration measured at Day 1 showed mean peak atosiban concentration (C(max)) 0.40, 0.57, 1.95 microg/ml for low, mid and high dose treated animals and mean peak concentration on Day 28 was 0.41, 0.88, 1.31microg/ml on Day 28 for low, mid and high dose treated animals.",Quantitative determination of oxytocin receptor antagonist atosiban in rat plasma by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356809/),[μg] / [ml],0.41,252658,DB00107,Oxytocin
,20356809,peak concentration,"Atosiban plasma concentration measured at Day 1 showed mean peak atosiban concentration (C(max)) 0.40, 0.57, 1.95 microg/ml for low, mid and high dose treated animals and mean peak concentration on Day 28 was 0.41, 0.88, 1.31microg/ml on Day 28 for low, mid and high dose treated animals.",Quantitative determination of oxytocin receptor antagonist atosiban in rat plasma by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356809/),[μg] / [ml],0.88,252659,DB00107,Oxytocin
,20356809,peak concentration,"Atosiban plasma concentration measured at Day 1 showed mean peak atosiban concentration (C(max)) 0.40, 0.57, 1.95 microg/ml for low, mid and high dose treated animals and mean peak concentration on Day 28 was 0.41, 0.88, 1.31microg/ml on Day 28 for low, mid and high dose treated animals.",Quantitative determination of oxytocin receptor antagonist atosiban in rat plasma by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356809/),[μg] / [ml],1.31,252660,DB00107,Oxytocin
,17904215,plasma oxytocin,"During the expulsive stage the overall mean (+/-S.D.) plasma oxytocin concentration was 12.9+/-13.9 pg/ml, with mean values in individual dogs ranging from 3.5 to 46 pg/ml.",Plasma oxytocin concentrations during late pregnancy and parturition in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904215/),[pg] / [ml],12.9,256004,DB00107,Oxytocin
,17904215,concentration,"During the expulsive stage the overall mean (+/-S.D.) plasma oxytocin concentration was 12.9+/-13.9 pg/ml, with mean values in individual dogs ranging from 3.5 to 46 pg/ml.",Plasma oxytocin concentrations during late pregnancy and parturition in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904215/),[pg] / [ml],12.9,256005,DB00107,Oxytocin
,17904215,peak plasma oxytocin level,"During the expulsive stage, the peak plasma oxytocin level in individual dogs ranged between 10 and 117 pg/ml.",Plasma oxytocin concentrations during late pregnancy and parturition in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904215/),[pg] / [ml],10 and 117,256006,DB00107,Oxytocin
,9065134,Sensitivity,Sensitivity of the assay was 1.5 pg/ml.,The pharmacokinetics of oxytocin as they apply to labor induction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065134/),[pg] / [ml],1.5,256535,DB00107,Oxytocin
,9065134,metabolic clearance rates,Mean oxytocin levels and metabolic clearance rates were 26.6 pg/ml and 7.97 ml/min.,The pharmacokinetics of oxytocin as they apply to labor induction. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065134/),[ml] / [min],7.97,256536,DB00107,Oxytocin
,28556962,half-life,"Retosiban was rapidly absorbed after oral administration, with an observed half-life of 1.45 h.",Treatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28556962/),h,1.45,258652,DB00107,Oxytocin
,8437126,urinary excretion,The 24-h urinary excretion ranged from 14.3 to 25.6% of the i.v. dose and was negatively correlated with peptide lipophilicity.,Pharmacokinetic and pharmacologic properties of antiuterotonic oxytocin analogs in the rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437126/),%,14.3 to 25.6,261281,DB00107,Oxytocin
,8222299,clearance,"The clearance of antocin was 23.5 +/- 7.6 l/h, the volume of distribution was 13.1 +/- 3.8 l and the biological half-life was 39.0 +/- 4.1 minutes.","Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222299/),[l] / [h],23.5,261775,DB00107,Oxytocin
,8222299,volume of distribution,"The clearance of antocin was 23.5 +/- 7.6 l/h, the volume of distribution was 13.1 +/- 3.8 l and the biological half-life was 39.0 +/- 4.1 minutes.","Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222299/),l,13.1,261776,DB00107,Oxytocin
,8222299,biological half-life,"The clearance of antocin was 23.5 +/- 7.6 l/h, the volume of distribution was 13.1 +/- 3.8 l and the biological half-life was 39.0 +/- 4.1 minutes.","Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222299/),min,39.0,261777,DB00107,Oxytocin
,9640267,area under the curve,"The mean amplitude and amount of oxytocin released, as calculated by the area under the curve of ovarian oxytocin pulses, were 6.27 +/- 1.98 ng min-1 and (10.05 +/- 8.91 ng min-1)tau, respectively (where tau is the number of hours between the last time point before and the first time point after a significant increase in hormone concentration was detected by the Pulsar program).",Stimulation of ovarian oxytocin secretion and uterine prostaglandin release by exogenous progesterone early in the cycle of the ovarian auto-transplanted ewe. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640267/),[ng] / [min],10.05,262099,DB00107,Oxytocin
,9640267,amplitude,"The mean amplitude and area under the curve of PGFM pulses were 317.22 +/- 5.65 pg ml-1 and (383.36 +/- 1.77 pg ml-1)tau, respectively.",Stimulation of ovarian oxytocin secretion and uterine prostaglandin release by exogenous progesterone early in the cycle of the ovarian auto-transplanted ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640267/),[pg] / [ml],317.22,262100,DB00107,Oxytocin
,9640267,area under the curve,"The mean amplitude and area under the curve of PGFM pulses were 317.22 +/- 5.65 pg ml-1 and (383.36 +/- 1.77 pg ml-1)tau, respectively.",Stimulation of ovarian oxytocin secretion and uterine prostaglandin release by exogenous progesterone early in the cycle of the ovarian auto-transplanted ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640267/),[pg] / [ml],383.36,262101,DB00107,Oxytocin
,9640267,number,The average number of pulses of plasma PGFM observed per ewe was 5.8 +/- 1.9 and interpulse interval for plasma PGFM pulses was 10.32 +/- 8.7 h between day 7 and day 9 after oestrus.,Stimulation of ovarian oxytocin secretion and uterine prostaglandin release by exogenous progesterone early in the cycle of the ovarian auto-transplanted ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640267/),,5.8,262102,DB00107,Oxytocin
,9640267,interpulse interval,The average number of pulses of plasma PGFM observed per ewe was 5.8 +/- 1.9 and interpulse interval for plasma PGFM pulses was 10.32 +/- 8.7 h between day 7 and day 9 after oestrus.,Stimulation of ovarian oxytocin secretion and uterine prostaglandin release by exogenous progesterone early in the cycle of the ovarian auto-transplanted ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640267/),h,10.32,262103,DB00107,Oxytocin
,31856330,T1/2λZ,"The longest T1/2λZ was 0.85 hr, indicating carbetocin was absorbed and eliminated rapidly in both animal species after administration.",Pharmacokinetics and bioavailability of carbetocin after intravenous and intramuscular administration in cows and gilts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856330/),h,0.85,263538,DB00107,Oxytocin
more,31856330,bioavailability,"The bioavailability was more than 80% in cows, suggesting administration via the IM route is efficient.",Pharmacokinetics and bioavailability of carbetocin after intravenous and intramuscular administration in cows and gilts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856330/),%,80,263539,DB00107,Oxytocin
,31856330,bioavailability,"However, the IV route is recommended for gilts due to a lower bioavailability (35%) and shorter T1/2λZ after IM administration compared with IV.",Pharmacokinetics and bioavailability of carbetocin after intravenous and intramuscular administration in cows and gilts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856330/),%,35,263540,DB00107,Oxytocin
,14614251,recovery,The average recovery was 86%.,Development of a radioreceptor assay for measuring an oxytocin antagonist in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14614251/),%,86,265152,DB00107,Oxytocin
,8126695,IC50,A number of analogues in the TP series that incorporate a modified or unmodified L-methionine sulfone amide at the C2 endo position on the camphor ring exhibit high affinity for OT receptors (IC50 = 1.3-15 nM) and good selectivity for binding to OT versus arginine vasopressin V1a and V2 receptors.,"1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),nM,1.3-15,274111,DB00107,Oxytocin
,8126695,IC50,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),nM,8.9,274112,DB00107,Oxytocin
,8126695,IC50,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),nM,26,274113,DB00107,Oxytocin
,8126695,oral bioavailability,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),%,35,274114,DB00107,Oxytocin
,8126695,oral bioavailability,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),%,25,274115,DB00107,Oxytocin
,8126695,oral bioavailability,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),%,21,274116,DB00107,Oxytocin
